# Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE

> **NCT07318259** · PHASE1 · RECRUITING · sponsor: **Chongqing Precision Biotech Co., Ltd** · enrollment: 18 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **BIOLOGICAL:** BCMA/CD70 CAR-T cells

## Key facts

- **NCT ID:** NCT07318259
- **Lead sponsor:** Chongqing Precision Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-26
- **Primary completion:** 2026-07
- **Final completion:** 2028-08
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07318259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07318259, "Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07318259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*